Opinion on  Pulmo BioTech Inc. (PLMO)
Pulmo BioTech Inc. (PLMO.OB) Recently Announced Potential MRI Applications for PulmoBind

Pulmo BioTech Inc. (PLMO.OB) Completes DFH-12 Studies

Pulmo BioTech Incorporated announced this week that its subsidiary, PulmoScience Incorporated, has completed the bio-distribution studies on its DFH-12 product candidate for the PulmoBind technology of molecular imaging of the lung’s vascular system. The completion of this study is a milestone for the company, proving the success of their molecule, code named DFH-12, and its application in other imaging technologies.

DFH-12 works, via injection, because the molecule is designed to bond only to the inner walls of the vascular system of the lungs. The DFH-12 molecule is tagged with a radionuclide, so the integrity of the lung’s vascular system can be imaged using the gamma cameras present in all hospitals with nuclear medicine imaging departments.

The new molecule’s success was demonstrated in several independent cases that showed the molecule is predominantly retained in the lungs for 30 minutes after injection, with only minor retention (~ 1/10th) in the liver and heart. The study also showed that the molecule is quickly eliminated from the body, with dispersion rates through the kidneys and bladder complete after 240 minutes.

The study shows the effectiveness of DFH-12 with gamma cameras, but the company believes that there are several other useful applications for its product line, including MRI and CT scanners. If successful, the company will change the landscape of nuclear medicine and its ability to diagnose conditions like pulmonary embolism, pulmonary hypertension and lung inflammation.

Please see disclaimer on QualityStocks.net website: http://Disclaimer.QualityStocks.net

PulmoBioTech, Inc. (PLMO.OB) Introduces New Molecular Imaging Agent

In the field of nuclear medicine, it is necessary to perfect non-invasive diagnostic methods, and PulmoBioTech is contributing greatly to this need. The company recently announced the completion of bio-distribution studies concerning its PulmoBind molecular imaging agent.

The process of imaging on a cellular level requires the use of specialized molecules which are chemically engineered to bind to specific cells in the body, and these are then bonded to radioactive tracers. PulmoBind is a bonding agent that has been found to surpass those traditionally used in the field on several points. Essentially, it is a totally harmless substance known as adreno medullin which, upon injection, travels to and bonds with the tissue in the lungs more effectively than commonly used albumin macro-aggregates (AMAs). PulmoBind is safer as well, and provides the ability to capture images that are not possible with the older method.

Perhaps the best reason to consider PulmoBind a significant advancement in medicine is that, unlike AMAs, it will cause absolutely no damage to the patient’s lungs. The substance serves its purpose, and is subsequently flushed from the body via the kidneys and bladder in a matter of four hours. Not to mention that this is all possible without requiring hospitals to purchase expensive equipment upgrades; PulmoBind simply replaces the obsolete AMAs. The scientists at PulmoBioTech are not only offering progress to patients with pulmonary problems, but to the entire field of nuclear medicine.

Please see disclaimer on QualityStocks.net website: http://Disclaimer.QualityStocks.net